Regentis Biomaterials (RGNT) on Wednesday filed a registration statement covering the potential resale of up to 3.81 million ordinary shares issued or issuable in connection with a June private placement.
The company said it will not receive proceeds from sales of the shares by the selling shareholders but may receive proceeds if the associated warrants are exercised for cash.
Shares of Regentis were up 1.6% in after-hours trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.